Urolithin A

Urolithin A is a small molecule your gut bacteria normally make from ellagitannins (pomegranate, walnut, certain berries) — and its job is to trigger mitophagy, the cellular process that clears damaged mitochondria. ~30–40% of Western adults can't produce it endogenously because they lack the right gut bugs (Gordonibacter, Ellagibacter), so direct supplementation (Amazentis Mitopure or generic ~500 mg/day) bypasses the microbiome and reliably elevates plasma UA. Three real RCTs (Andreux 2019 Phase 1, Liu 2022 Phase 2 muscle endurance, Singh 2022 ATLAS-cited muscle improvement at 4 months) show consistent, modest, age-stratified benefits in older adults: improved mitochondrial gene expression, drops in C-acylcarnitine biomarkers of mitochondrial dysfunction, and small-but-real muscle endurance gains. For Dylan at 20: OPTIONAL-ADD with MEDIUM-HIGH confidence in the evidence but LOW expected delta given his profile — young trained mitochondria don't have much room to improve. Revisit at 30+, or earlier if a urinary metabolite test confirms he's a non-producer (real physiological gap to fill).

Origin — the microbiome conversion problem. Ellagitannins are large polyphenols abundant in pomegranate (whole fruit, juice), walnuts, raspberries, strawberries, certain teas, and Mediterranean nuts. Humans cannot digest ellagitannins directly — they pass intact to the colon, where specific gut bacteria (primarily Gordonibacter species — G. urolithinfaciens, G. pamelaeae — and Ellagibacter isourolithinifaciens) hydrolyze them via the lactonase/decarboxylase pathway through intermediates ellagic acid → urolithin M5/M6/D → C → A → B. Urolithin A (UA) is the most bioactive intermediate, peaking at the "metabotype A" pattern of conversion. Critically: only ~30–40% of Western adults harbor sufficient Gordonibacter/Ellagibacter to produce significant plasma UA after a pomegranate load. Another ~25–35% are "metabotype B" producers (urolithin B-dominant — less bioactive). The remainder are "metabotype 0" non-producers — they convert minimally and stop at upstream intermediates. Direct UA supplementation bypasses this entire microbiome bottleneck.

Pathway 1 — Mitophagy induction (the headline mechanism). Mitophagy is the lysosomal degradation of damaged mitochondria — a quality-control system that shifts the mitochondrial population toward younger, healthier units. The canonical pathway is PINK1 (PTEN-induced kinase 1) → Parkin → ubiquitination of damaged mitochondrial outer-membrane proteins → recognition by autophagy receptors (NDP52, OPTN, p62/SQSTM1) → engulfment by autophagosomes → fusion with lysosomes → degradation. UA is one of the few well-characterized small-molecule mitophagy inducers in humans. Mechanism details: UA stabilizes PINK1 on the outer mitochondrial membrane in cells with mild mitochondrial stress, recruits Parkin, and increases LC3-II flux through the autophagy machinery. UA also induces receptor-mediated mitophagy via BNIP3/BNIP3L and FUNDC1 pathways (the "Parkin-independent" arm). Net effect at the cell-population level: fewer dysfunctional mitochondria, higher mean membrane potential per mitochondrion, increased oxidative capacity per unit muscle.

Pathway 2 — Mitochondrial biogenesis (downstream consequence). When damaged mitochondria are cleared, the cell compensates by upregulating new mitochondrial production: PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) transcription rises, TFAM (mitochondrial transcription factor A) activates mtDNA replication, and NRF1/NRF2 drive nuclear-encoded mitochondrial gene expression. The Andreux 2019 Phase 1 trial confirmed this: 4 weeks of 500–1000 mg UA in healthy older adults produced a significant skeletal-muscle gene-expression signature consistent with mitochondrial biogenesis (PGC-1α-axis genes upregulated). This is the strongest non-trivial human mechanistic confirmation of any longevity-marketed supplement.

Pathway 3 — Plasma C-acylcarnitine reduction. Acylcarnitines are intermediates of fatty acid β-oxidation; elevated plasma levels signal mitochondrial dysfunction (incomplete fat oxidation, accumulated intermediates spilling into circulation). UA dose-dependently reduces specific acylcarnitines (C2 acetylcarnitine, C16 palmitoylcarnitine, C18 stearoylcarnitine, C18:1 oleoylcarnitine) in human plasma over 4–16 weeks. This is a clean biomarker confirmation that UA is hitting mitochondrial fat metabolism in vivo, not just cell-culture artifact.

Pathway 4 — Anti-inflammatory effect via NLRP3 suppression. UA inhibits NLRP3 inflammasome activation in macrophages, reducing IL-1β and IL-18 production. This produces a modest hsCRP reduction in human trials (smaller effect than the mitochondrial endpoints). Likely contributes to muscle endurance benefit by reducing chronic low-grade inflammation in aging skeletal muscle.

Pathway 5 — Senescence-associated effects (preclinical only). UA reduces senescence-associated secretory phenotype (SASP) markers in cell culture and shows mild senolytic activity in some preclinical models. Not yet validated as a senolytic in humans. Distinct mechanism from the mitophagy core.

Plain English: Your mitochondria are like the engines in your cells. They wear out, accumulate damage, and start running inefficiently. Mitophagy is the body's process for scrapping the worn-out engines and building new ones. Urolithin A switches that process on. In old animals and 50+ humans, it produces measurable improvements in muscle endurance, mitochondrial gene expression, and plasma biomarkers. In young, trained athletes, mitochondrial quality is already near peak — the room for benefit is much narrower. The "do you produce UA endogenously" question matters: if your gut bacteria don't make it from your diet (~30–40% of Western adults), you're missing a physiological signal that direct supplementation restores. That's a clean rationale even at age 20 — but you'd need to confirm non-producer status to know if it applies.